Stem cell transplant using your own cells for AL amyloidosis
Part of Blood & lymphatic, Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18–75 years old
- You have newly diagnosed AL amyloidosis
- Your blood or urine tests show abnormal M protein or abnormal free light chains
- A specialist says you are a good candidate for an autologous stem cell transplant
- Your daily function is fairly good (ECOG 0–2)
- You can (or your legal representative can) sign consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment using your own immune cells, modified in the lab, to target and destroy the cells that cause AL amyloidosis. It is for people who are newly diagnosed and have severe heart involvement, with the goal of slowing or stopping the disease.
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.